{"id":"W4366824059","doi":"10.1038/s41591-023-02326-3","title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Douglas Mental Health University Institute","funders":"University College London; Ionis Pharmaceuticals; Biogen","keywords":"Pathophysiology; Placebo; Alzheimer's disease; Disease; Tau protein; Oligonucleotide; Medicine; Pharmacology; Neuroscience; Internal medicine; Biology; Pathology; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002689281,0.0005987266,0.002496823,0.001079296,0.0001826406,0.00002651478,0.0002299317,0.0003755445,0.0006169408],"category_scores_gemma":[0.005260627,0.0003922945,0.0006077385,0.001406003,0.0004851925,0.0001413222,0.000101417,0.001380333,0.0003399738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001253671,"about_ca_system_score_gemma":0.0004950953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001126619,"about_ca_topic_score_gemma":0.00001364806,"domain_scores_codex":[0.9945499,0.0006872899,0.001129122,0.0008516386,0.001646572,0.001135522],"domain_scores_gemma":[0.9957743,0.001707278,0.0002701853,0.0006537371,0.000238471,0.001355979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9558281,0.001943486,0.0003844562,0.00009736729,0.006515433,0.007141668,0.0002022329,0.000004013539,0.0001686628,0.0001629212,0.02622287,0.001328744],"study_design_scores_gemma":[0.9886395,0.0008823361,0.0006484639,0.0006946151,0.004505181,0.00002240692,0.0001727156,0.00244513,0.0001902768,0.0003038918,0.001189327,0.0003062022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.857963,0.10783,0.000008746901,0.01597778,0.001368983,0.01380479,0.00008438982,0.0004936932,0.002468588],"genre_scores_gemma":[0.9917062,0.002550013,0.0001125249,0.001097376,0.001918484,0.001093234,0.0009687067,0.0001037067,0.0004497552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1337432,"threshold_uncertainty_score":0.9998529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02776427307319292,"score_gpt":0.3711127497206226,"score_spread":0.3433484766474297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}